# How much optimism can Bullish Peptides justify?

> Bullish Peptides weighs reasons for optimism: semaglutide heart outcomes, tirzepatide weight loss, tesamorelin fat changes and the gaps around MOTS-c.

A semaglutide trial counted heart attacks, strokes and cardiovascular deaths. Fewer happened with treatment. I’m bullish about that result, with a very specific claim to defend.

## The SELECT result

SELECT enrolled 17,604 adults with established cardiovascular disease, a body-mass index of at least 27. None had diabetes. Its main outcome combined cardiovascular death, nonfatal heart attack and nonfatal stroke. Semaglutide [reduced the risk of that combined outcome by 20% relative to placebo](https://pubmed.ncbi.nlm.nih.gov/37952131/). That finding makes a stronger case for optimism than another account of a smaller clothing size.

SELECT makes a convincing case for my optimism. These people already had cardiovascular disease; preventing a first event in otherwise healthy adults would be a different claim. And a lower combined result does not establish that every component fell separately. The result is substantial enough to deserve its actual boundaries.

## Four compounds

The name Bullish Peptides began with a question: where does enthusiasm have something solid underneath it? There are convincing human treatment results here. There are also intriguing experiments whose greatest contribution, so far, is a better question. My confidence drops at the jump from an animal experiment to a human claim.

- [Semaglutide](/semaglutide) has separate trials for [weight loss](https://pubmed.ncbi.nlm.nih.gov/33567185/), the SELECT cardiovascular outcome and [serious kidney-related outcomes in type 2 diabetes with chronic kidney disease](https://pubmed.ncbi.nlm.nih.gov/38785209/).
- [Tirzepatide](/tirzepatide) produced [greater average weight loss than semaglutide in a direct obesity comparison](https://pubmed.ncbi.nlm.nih.gov/40353578/). That is a claim about the outcome measured in that trial.
- [Tesamorelin](/tesamorelin) reduced [fat around abdominal organs in adults with HIV-associated fat accumulation](https://pubmed.ncbi.nlm.nih.gov/25038357/). Location matters as much as the amount.
- [MOTS-c](/mots-c) improved [glucose handling in mouse experiments](https://pubmed.ncbi.nlm.nih.gov/25738459/). Its human treatment case still needs to be built.

## Conditions on the optimism

A benefit can depend on continuing treatment. In the longer tesamorelin study, [visceral fat returned after discontinuation](https://pubmed.ncbi.nlm.nih.gov/18690162/). That makes durability a practical question, even when the initial result is convincing. Safety also changes the calculation: semaglutide’s [digestive symptoms and increased biliary-disease risk](https://pubmed.ncbi.nlm.nih.gov/34305810/) sit beside its benefits.

I object when optimism spends the same result twice—first as a measured benefit, then as permission to assume everything else improved. The [comparison](/compare) puts the strongest claims beside the questions they leave open. The [answers page](/faq) deals with appetite, muscle and research labels. This is an encouraging body of work with uneven reach; the unevenness is where it gets interesting.

---

Bullish Peptides is an independent cohort-first literature digest—not a clinic, a peptide counter, or a permission slip to outrun the evidence.